Communication and Dissemination — WP6

  • Key actions for WP6

  • Develop and implement a communication strategy to promote NANOSPRESSO and its technological breakthroughs.

  • Ensure strategic dissemination of project results to stakeholders, including the pharmaceutical industry, regulators, and patient communities.

  • Lead public outreach to ensure sustainability, future exploitation, and industry partnerships for NANOSPRESSO's technology.

Leader of WP6

Dr. Alexandre Ceccaldi

General Secretary – ETPN (European Technology Paltform on Nanomedicine)

Short bio:

Dr. Alexandre Ceccaldi is dedicated to the adoption of nanomedicine across Europe, bridging the gap between research, industry, and clinical application. He holds a PhD in biology from Université Pierre et Marie Curie, and an engineering degree from Agro ParisTech. Since 2015, he has been the General Secretary of the European Technology Platform on Nanomedicine (ETPN). He coordinates a community of over 130 member institutions from 27 countries across Europe, including academia, SMEs, industry, healthcare providers, and policy makers. ETPN supports both fundamental research in nanomaterials and nanosciences, as well as fosters their clinical translation.

Dr. Ceccaldi has participated in multiple European R&D initiatives, including coordinating the NOBEL project (H2020), which aimed to facilitate the convergence of health technologies across Europe. He is also a work package leader in the METRINO project (focused on standardizing metrology for nanomedicine) and in the NANOSPRESSO project. He has played a key role in the creation of the HealthTech4EU Alliance, Europe’s first cross-technology healthcare platform. In 2023, he was elected Chair of the Strategic Advisory Board of the ERA4Health EU funding program.

Dr. Ceccaldi is passionate about fostering connections to advance innovative clinical solutions, transforming them into life-changing outcomes for patients. His main focus is to help making a real difference on unmet clinical needs, keeping in mind that patients don't care about technology, they care about quality of life.

Involved Partners

All partners contributing to dissemination and communication activities

Results

We are collecting results that will be posted here soon. Stay tuned.

LOCAL PREPARATION OF HIGH-QUALITY, PERSONALISED NUCLEIC ACID NANOMEDICINES

NANOSPRESSO is funded by the Dutch Research Agenda (NWA) ORC 2020/21 program. For more information about our partners, funding, and legal notices, please visit our contact page and follow us on social media.